Ctca

CTCA is a CT scan of the coronary arteries, not a treatment. It is a diagnostic test, so the burden-of-proof question is whether it gives you information worth the radiation and contrast.

The evidence here is about how well the test works, not about any intervention. In emergency chest pain, CTCA shortens hospital stays and gets more people discharged directly from the ER, but it also leads to more downstream testing and higher radiation exposure than standard care [4]. One randomized trial of 1,000 patients found CTCA cut average length of stay from about 31 hours to 23 hours, but cumulative radiation was about 14 mSv versus 5 mSv for standard evaluation [4]. Costs were similar [4].

The test's real strength is ruling disease out. In low-to-intermediate risk patients, CTCA shows very high sensitivity and negative predictive value, around 99% in the ACCURACY trial [2]. The weakness is specificity, around 83%, meaning it flags some people who do not actually have significant blockages [2]. That is why it can trigger extra testing.

Radiation doses have dropped sharply with newer protocols. One large series cut median dose from about 18 mSv to 1.6 mSv using low-dose techniques [1]. A 2022 Thai cohort reported a mean of about 2.9 mSv for CTCA versus 5.6 mSv for invasive angiography [3].

The evidence is mostly from trials funded through academic centers, not manufacturers, which is a point in its favor. But no study here tracks long-term outcomes from the radiation exposure. The trade-off is real: faster answers and fewer admissions, at the cost of more radiation and more follow-up tests.

My call: CTCA is a reasonable diagnostic tool for ruling out coronary disease in low-risk chest pain, but it is not a screening test for healthy people. Confidence: moderate.